Standout Papers

Efficacy and safety of selective TYK2 inhibit... 2017 2026 2020 2023 368
  1. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis (2022)
    Philip J. Mease, Atul Deodhar et al. Annals of the Rheumatic Diseases
  2. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis (2021)
    Iain B. McInnes, J. Anderson et al. New England Journal of Medicine
  3. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors (2017)
    Dafna D. Gladman, William F. C. Rigby et al. New England Journal of Medicine

Immediate Impact

1 by Nobel laureates 7 from Science/Nature 69 standout
Sub-graph 1 of 20

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
2024 Standout
2 intermediate papers

Works of Frank Behrens being referenced

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
2017 Standout
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double‐blind, randomized, placebo‐controlled clinical trial
2004
and 1 more

Author Peers

Author Last Decade Papers Cites
Frank Behrens 2344 2310 1330 173 3.5k
Kurt de Vlam 3066 1912 1394 165 3.7k
J. Wollenhaupt 3970 2262 2046 124 5.1k
Elizabeth C. Hsia 2973 1600 1601 105 3.8k
Luminita Pricop 2603 3466 1612 113 4.6k
Rubén Queiró 1796 1894 866 189 2.9k
Antonio Marchesoni 5046 3538 2264 142 6.2k
Mitsumasa Kishimoto 1744 1017 769 154 2.7k
Luisa Costa 2035 1824 969 127 3.3k
H. Küpper 4425 2328 2030 127 5.7k
Francesco Caso 1993 1827 1017 135 3.8k

All Works

Loading papers...

Rankless by CCL
2026